newsfilter
← Latest News
Business Wire·

Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

– Median Overall Survival for QINLOCK® of 35.5 Months Versus 31.5 Months for Sunitinib in the All-Patient Intent-to Treat-Population – – Long-Term Safety Profile Consistent with Primary Analysis Showing Fewer